Omeprazole is a benzimidazole derivative, a weak base and is lipophilic in nature. This compound is pH sensitive and does not exists in its original form at low pH.
Omeprazole has been used as an atypical cytochrome P450 (CYP) 1A2 inducer in Dulbecco′s modified eagle′s medium (serum free) to study the effects of inducers on CYP activities in human hepatocytes and also to compare with other classical aryl hydrocarbon receptor ligands.
Omeprazole binds covalently to proton pump (H+, K+-ATPase) and inhibits gastric secretion. It is useful in ameliorating the effects of peptic oesophagitis, duodenal and gastric ulcer. Omeprazole is preferred over antagonists of histamine H2-receptor and ranitidine for its higher efficiency. It is also useful in treating Zollinger-Ellison syndrome.
Features and Benefits
This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm. This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.